HOME >> BIOLOGY >> NEWS
Hemocellular Therapeutics establishes licensing agreement with UNC, ECU

CHAPEL HILL -- Hemocellular Therapeutics, expected to produce the first platelet-based therapeutic available to doctors for the immediate treatment of active bleeding, has established an exclusive licensing agreement with the University of North Carolina at Chapel Hill and East Carolina University, company officials recently announced.

The agreement recognizes key technology developed by researchers at the two universities as central to the N.C. company's planned creation of lyophilized, or "freeze-dried," human platelets the component of blood primarily responsible for initiation of coagulation. As a part of the exclusive license agreement, both universities received equity in Hemocellular and will share in royalties on the eventual sale of products.

Hemocellular's freeze-dried platelets are the result of a decade of research supported by initial federal research funding of $10 million.

The company's scientific founders, Dr. Arthur P. Bode of ECU and Dr. Thomas H. Fischer of UNC, have led the research efforts. Bode, who received his doctorate in experimental pathology from UNC, has served as ECU's scientific director of clinical coagulation programs for 15 years.

Fischer is scientific director of UNC's Francis Owen Research Laboratory, where researchers discovered the molecular cell membrane cross-linking technology crucial to Hemocellular's product development, said Richard A. Basile, chief executive officer of the company, and the initial extensive series of trials have taken place at that lab.

"The Francis Owen lab has a worldwide reputation in the field of coagulation therapeutics. We are extremely fortunate to have researchers affiliated with this lab informing our efforts to bring this technology to health-care settings as rapidly and responsibly as possible," he said.

Basile added that the licensing agreement is key in advancing platelet development to the next stage: human clinical trials. No other func
'"/>

Contact: Deb Saine
919-962-8415
University of North Carolina at Chapel Hill
15-May-2003


Page: 1 2 3

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
4. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
5. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
6. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
7. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
8. Immerge BioTherapeutics announces identification of PERV receptor
9. Acorda Therapeutics acquires CeNeS neuregulin products
10. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
11. Genome Therapeutics, University of Southampton and Schering-Plough identify novel asthma gene

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... June 13, 2019 , ... KICVentures announced today its plans ... Orthopedic and Pain Management-Driven ASC Conference in Chicago on Thursday, June 13th at 6:30 ... Dr. Chicago, IL in the 3rd floor Ticino Hospitality room in space #74T. , ...
(Date:6/11/2019)... ... 10, 2019 , ... Improved Pharma LLC announces the publication of “Predictive and ... The article was published online on April 29th, 2019. The authors are Stephen ... Chen of Purdue University. , The article is the most recent addition to a ...
(Date:6/6/2019)... ... June 05, 2019 , ... Ziegler, a ... advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent acquisition by PathGroup. ... that provides services to more than one dozen hospitals and surgery centers in ...
Breaking Biology News(10 mins):
(Date:6/18/2019)... ... June 17, 2019 , ... ... entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) ... rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 ...
(Date:6/11/2019)... CITY, Calif. (PRWEB) , ... June 10, 2019 ... ... (IOPP) today announced IOPP will add 80 of its scientific journals to DeepDyve’s ... of physics-related content to DeepDyve’s continually expanding library of more than 20 million ...
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the primary forms ... cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric ... with engineered T cell receptors known as “CARs”. The CAR enables the final product ...
(Date:5/22/2019)... ... 22, 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation ... round co-led by Astanor Ventures and Talis Capital with participation ... iSelect Fund . The company has raised $11.75m to date and will use the ...
Breaking Biology Technology:
Cached News: